Edition:
United States

Intra-Cellular Therapies Inc (ITCI.OQ)

ITCI.OQ on NASDAQ Stock Exchange Global Select Market

14.90USD
3:59pm EST
Change (% chg)

$-0.20 (-1.32%)
Prev Close
$15.10
Open
$15.11
Day's High
$15.58
Day's Low
$14.75
Volume
112,446
Avg. Vol
249,759
52-wk High
$22.65
52-wk Low
$7.85

Chart for

About

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system... (more)

Overall

Beta: 0.75
Market Cap(Mil.): $875.65
Shares Outstanding(Mil.): 53.10
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Intra-Cellular Therapies receives FDA fast track designation for Schizophrenia treatment drug

* Intra-Cellular Therapies receives FDA fast track designation for lumateperone for the treatment of schizophrenia

Nov 20 2017

BRIEF-Intra-Cellular starts enrollment in ITI-214 clinical trial in patients with Parkinson’s disease

* Intra-Cellular therapies announces commencement of enrollment of a clinical trial evaluating ITI-214 in patients with Parkinson’s disease Source text for Eikon: Further company coverage:

Oct 03 2017

BRIEF-Intra-Cellular announces proposed public offering of common stock

* Intra-Cellular Therapies announces proposed public offering of common stock

Sep 26 2017

BRIEF-BB Biotech reports 5.1 pct passive stake in Intra-Cellular Therapies

* BB Biotech AG reports 5.1 percent passive stake in Intra-Cellular Therapies Inc as of August 18, 2017 - SEC filing‍​ Source text: (http://bit.ly/2xcLrz4) Further company coverage:

Aug 23 2017

Earnings vs. Estimates